In an independent study, eliminating CD4+ T cells or NK1.1+ NK cells individually did not impair tumor response to DCP-IL-12/FLT3L treatment (Extended Data Fig. 7l,m), and disrupting CD4+ T cells was associated with compensatory increases in both total and activated (IFNγ+ or GZMB+) CD8+ T cells (Extended Data Fig. 7n,o). The gene discussed is FLT3LG; the disease is neoplasm.